Enlivex Granted EU Orphan Drug Designation for Lead Product ApoCell for Graft-Versus-Host Disease

Enlivex Therapeutics , a Hadasit Bio-Holdings portfolio company, today announced that the European Medicines Agency has granted orphan drug status to the Company's lead product candidate, ApoCell, for the prevention of Graft-versus-Host Disease . Previously, ApoCell received orphan drug designation from the U.S. Food & Drug Administration .

http://ift.tt/1zOkSy9